Emergent BioSolutions Files 8-K
Ticker: EBS · Form: 8-K · Filed: Jan 15, 2025 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | 8-K |
| Filed Date | Jan 15, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
TL;DR
Emergent BioSolutions filed an 8-K on Jan 15, 2025. Standard disclosure, no major news yet.
AI Summary
Emergent BioSolutions Inc. filed an 8-K on January 15, 2025, reporting on Regulation FD disclosures and financial statements. The filing details the company's principal executive offices located at 300 Professional Drive, Gaithersburg, Maryland, 20879, and its primary business phone number as (240) 631-3200. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Emergent BioSolutions is providing updates or disclosures required by the SEC, which could contain important information for investors regarding the company's operations or financial status.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a change in risk.
Key Players & Entities
- Emergent BioSolutions Inc. (company) — Registrant
- January 15, 2025 (date) — Date of earliest event reported
- 300 Professional Drive, Gaithersburg, Maryland, 20879 (location) — Principal executive offices
- (240) 631-3200 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Emergent BioSolutions Inc.?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, intended to cover Regulation FD disclosures and financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported is dated January 15, 2025.
Where are Emergent BioSolutions Inc.'s principal executive offices located?
The principal executive offices are located at 300 Professional Drive, Gaithersburg, Maryland, 20879.
What is the telephone number for Emergent BioSolutions Inc.?
The registrant's telephone number, including area code, is (240) 631-3200.
What is the SIC code for Emergent BioSolutions Inc.?
The Standard Industrial Classification (SIC) code for Emergent BioSolutions Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 555 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-01-15 15:45:19
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share EBS New York St
Filing Documents
- d916387d8k.htm (8-K) — 25KB
- d916387dex991.htm (EX-99.1) — 56KB
- g916387ex99_1s10g1.jpg (GRAPHIC) — 83KB
- g916387ex99_1s11g1.jpg (GRAPHIC) — 66KB
- g916387ex99_1s12g1.jpg (GRAPHIC) — 83KB
- g916387ex99_1s13g1.jpg (GRAPHIC) — 70KB
- g916387ex99_1s14g1.jpg (GRAPHIC) — 70KB
- g916387ex99_1s15g1.jpg (GRAPHIC) — 63KB
- g916387ex99_1s16g1.jpg (GRAPHIC) — 34KB
- g916387ex99_1s17g1.jpg (GRAPHIC) — 70KB
- g916387ex99_1s18g1.jpg (GRAPHIC) — 70KB
- g916387ex99_1s19g1.jpg (GRAPHIC) — 57KB
- g916387ex99_1s1g1.jpg (GRAPHIC) — 37KB
- g916387ex99_1s20g1.jpg (GRAPHIC) — 86KB
- g916387ex99_1s21g1.jpg (GRAPHIC) — 54KB
- g916387ex99_1s22g1.jpg (GRAPHIC) — 40KB
- g916387ex99_1s23g1.jpg (GRAPHIC) — 57KB
- g916387ex99_1s24g1.jpg (GRAPHIC) — 30KB
- g916387ex99_1s25g1.jpg (GRAPHIC) — 15KB
- g916387ex99_1s26g1.jpg (GRAPHIC) — 99KB
- g916387ex99_1s27g1.jpg (GRAPHIC) — 119KB
- g916387ex99_1s28g1.jpg (GRAPHIC) — 59KB
- g916387ex99_1s29g1.jpg (GRAPHIC) — 39KB
- g916387ex99_1s2g1.jpg (GRAPHIC) — 152KB
- g916387ex99_1s30g1.jpg (GRAPHIC) — 58KB
- g916387ex99_1s31g1.jpg (GRAPHIC) — 42KB
- g916387ex99_1s32g1.jpg (GRAPHIC) — 57KB
- g916387ex99_1s33g1.jpg (GRAPHIC) — 70KB
- g916387ex99_1s34g1.jpg (GRAPHIC) — 71KB
- g916387ex99_1s35g1.jpg (GRAPHIC) — 60KB
- g916387ex99_1s36g1.jpg (GRAPHIC) — 62KB
- g916387ex99_1s37g1.jpg (GRAPHIC) — 77KB
- g916387ex99_1s38g1.jpg (GRAPHIC) — 97KB
- g916387ex99_1s39g1.jpg (GRAPHIC) — 82KB
- g916387ex99_1s3g1.jpg (GRAPHIC) — 58KB
- g916387ex99_1s40g1.jpg (GRAPHIC) — 45KB
- g916387ex99_1s41g1.jpg (GRAPHIC) — 12KB
- g916387ex99_1s4g1.jpg (GRAPHIC) — 66KB
- g916387ex99_1s5g1.jpg (GRAPHIC) — 58KB
- g916387ex99_1s6g1.jpg (GRAPHIC) — 53KB
- g916387ex99_1s7g1.jpg (GRAPHIC) — 64KB
- g916387ex99_1s8g1.jpg (GRAPHIC) — 55KB
- g916387ex99_1s9g1.jpg (GRAPHIC) — 96KB
- 0001193125-25-007008.txt ( ) — 3854KB
- ebs-20250115.xsd (EX-101.SCH) — 3KB
- ebs-20250115_lab.xml (EX-101.LAB) — 17KB
- ebs-20250115_pre.xml (EX-101.PRE) — 11KB
- d916387d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits . Exhibit No. Description 99.1 Emergent BioSolutions Inc. corporate slide deck. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: January 15, 2025 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer